Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop

Journal of Bone and Mineral Research

Volumn 24, Issue 3, 2009, Pages 373-385

  Bilezikian, John P ^a   Matsumoto, Toshio ^b   Bellido, Teresita ^c   Khosla, Sundeep ^d   Martin, Jack ^a,e   Recker, Robert R ^f   Heaney, Robert ^f   Seeman, Ego ^g   Papapoulos, Socrates ^h   Goldring, Steven R ⁱ  

^a College of Physicians and Surgeons ^*  (United States)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c INDIANA UNIVERSITY   (United States)

^d Mayo Clinic   (United States)

^e ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^f CREIGHTON UNIVERSITY   (United States)

^g HEIDELBERG REPATRIATION HOSPITAL   (Australia)

^h LEIDEN UNIVERSITY   (Netherlands)

ⁱ HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CLOMIFENE; ESTROGEN RECEPTOR; FAT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SCLEROSTIN; SEX HORMONE; TAMOXIFEN; VITRONECTIN RECEPTOR; WNT PROTEIN;

BONE CELL; BONE DENSITY; BONE MASS; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; BREAST CANCER; CANCELLOUS BONE; DRUG MECHANISM; ENERGY METABOLISM; HUMAN; JAW OSTEONECROSIS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; REVIEW;

ANIMALS; BONE REMODELING; BONE RESORPTION; HUMANS; MICE; OSTEOGENESIS; OSTEOPOROSIS;

EID: 61849109895     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.090105     Document Type: Review

References (118)

1. Aaron JE, Makins NB, Sagreiy K 1987 The microanatomy of trabecular bone loss in normal aging men and women. Clin Orthop Relat Res 215:260-271.
2. Kholsa S. Melton LJ III, Achenbach SJ, Oberg AL, Riggs BL 2006 Hormonal and biochemical determinants of trabecular microstructure at the ultradistal radius in women and men. J Clin Endocrinol Metab 31:885-891.
3. Lips P, Courpron P, Meunier PJ 1978 Mean wall thickness of trabecular bone packets in the human iliac crest: Changes with age. Calcif Tissue Res 10:13-17.
4. Ericksen EF 1986 Normal and pathological remodeling of human trabecular bone: Three dimensional reconstruction of the remodelling sequence in normals and in metabolic disease. Endocr Rev 4:379-408.
5. Akhter MP, Lappe JM, Davies KM, Recker RR 2007 Trans-menopausal changes in the trabecular bone structure. Bone 41:111-116.
6. Parfitt AM, Travers R, Rauch F, Glorieux FH 2000 Structural and cellular changes during bone growth in healthy children. Bone 27:487-494.
7. Seeman E 2003 Periosteal bone formation: A neglected determinant of bone strength. N Engl J Med 349:320-323.
8. Ruff CB, Hayes WC 1988 Sex differences in age-related remodeling of the femur and tibia. J Orthop Res 6:886-896.
9. Kousteni S, Bilezikian JP 2008 Cellular actions of parathyroid hormone. In: Bilezikian JP, Raisz LG, Martin TJ (eds.) Principles of Bone Biology, 3rd ed. Elsevier-Academic Press, San Diego, CA. USA, pp. 639-656.
10. Heaney RP 1994 The bone remodeling transient: Implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res 9:1515-1523.
11. Heaney RP, Yates AJ, Santora AC II 1997 Bisphosphonate effects and the bone remodeling transient. J Bone Miner Res 12:1143-1151.
12. Heaney RP 2001 The bone remodeling transient: Interpreting interventions involving bone-related nutrients. Nutr Rev 59:327-333.
13. Robling AG, Castillo AB, Turner CH 2006 Bioechanical and molecular regulation of bone remodeling. Annu Rev Biomed Eng 8:455-498.
14. Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM 2008 Harris Se, Turner CH. Mechanical stimulation of bone in vivo reduces osteocyte expression of SOST/Sclerostin. J Biol Chem 283:5866-5875.
15. Seeman E, Delmas PD 2006 Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 354:2250-2261.
16. Keaveney TM 1998 Cancelous bonc. In: Black J, Hastings G (eds.). Handbook of Biomaterials Properties. Chapman & Hall. London, UK, pp. 15-23.
17. Zebaze RM, Jones A, Knackstedt M, Maalouf G. Seeman E 2007 Construction of the femoral neck during growth determines its strength in old age. J Bone Miner Res 22:1055-1061.
18. Loro ML, Sayre J, Roe TF, Goran Ml, Kaufman FR, Gilsanz V 2000 Early identification of children predisposed to low peak bone mass and osteoporosis later in life. J Clin Endocrinol Mctab 85:3908-3918.
19. Wang Q, Alen M, Nicholson P, Lyytikainen A, Suurubuenu M, Helkala E. Suominen H, Cheng S 2005 Growth patterns at distal radius and tibial shaft in pubertal girls: A 2-year longitudinal study. J Bone Miner Res 20:954-961.
20. Bonewald LF, Johnson ML 2008 Osteocytes, mechanosensing and Wnt signaling. Bone 42:606-615.
21. Clark WD, Smith EL, Linn KA, Paul-Murphy JR, Muir P, Cook ME 2005 Osteocyte apoptosis and osteoclast presence in chicken radii 0-4 days following osteotomy. Calcif Tissue Int 77:327-336.
22. Aguirre Jl, Plotkin LI, Stewart SA. Weinstein RS, Parfitt AM, Manolagas SC. Bellido T 2006 Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss. J Bone Miner Res 21:605-615.
23. Kurata K, Heino TJ, Higaki H, Väänänen HK 2006 Bone marrow cell differentiation induced by mcchanically damaged osteocytes in 3D gel-embedded culture. J Bone Miner Res 21:616-625.
24. Zhang K, Barragan-Adjemian C, Ye L, Kotha S, Dallas M, Lu Y, Zhao S, Harris M, Harris SE, Feng JQ, Bonewald LF 2006 Ell/gp38 selective expression in osteocytes: Regulation by mechanical strain and role in dendrite elongation. Mol Cell Biol 26:4539-4552.
25. Strom TM, Juppner H 2008 PHEX, FGF23, DMP and beyond. Curr Opin Nephrol Hypertens 17:357-362.
26. Gowen LC, Petersen DN, Mansolf AL Qi H, Stock JL, Tkalcevic CT, Simmons HA, Crawford DT, Chidsey-Frink KL, Ke HZ, McNeish JD, Brown TA 2003 Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem 278: 1998-2007.
27. Lane NE, Yao W, Balooch M, Nalla RK, Balooch G, Habelitz S, Kinney JH, Bonewald LF 2006 Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res 21:466-476.
28. Lee NK, Sowa H. Hinoi E, Ferron M, Deok A, Confavreux C. Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G 2007 Endocrine regulation of energy metabolism by the skeleton. Cell 130:456-469.
29. Kulterer B, Friedl G, Jandrositz A, Sanchez-Cabo F, Prokesch A, Paar C, Scheideler M, Windhager R, Preisegger KH, Trajanoski Z 2007 Gene expression profiling of human mesenchimal stem cells derived from bone marrow during expansion and osteoblast differentiation. BMC Genomics 12:70.
30. Di Iorgi N, Rosol M, Mittelman SD, Gilsanz V 2008 Reciprocal relation between marrow adiposity and the amount of bone in the axial and appendicular skeleton of young adults. J Clin Endocrinol Metab 93:2281-2286.
31. Rosen DJ 2007 The rosiglitazone story - lessons from an FDA Advisory Committee Meeting. N Eng J Med 357:844-846.
32. Kawaguchi H 2006 Molecular backgrounds of age-related osteoporosis from mouse genetics approaches. Rev Endocr Metab Disord 7:17-22.
33. Nelson-Dooley C, Della-Fera MA, Hamrick M, Baile CA 2005 Novel treatments for obesity and osteoporosis; targeting apoptotic pathways in adipocytes. Curr Med Chem 12:2215-2225.
34. Ross FP, Teitelbaum SL 2005 avB3 and M-CSF: Partners in osteoclast biology. Immunol Rev 208:88-105.
35. McHugh KP, Hodivala-Dilke K. Zheng MH. Namba N. Lam J, Novack D, Feng X, Ross FP, Hynes RO, Teitelbaum SL 2000 Mice lacking β3 integrines are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 105:433-440.
36. Faccio R, Zallone A, Ross FP, Teitelbaum SL 2003 C-Fms and the αvβ3 integrin collaborate during osteoclast differentiation. J Clin Invest 111:749-758.
37. Teitelbaum SL 2007 Osteoclasts: What do they do and how do they do it? Am J Pathol 170:427-435.
38. Hofbauer LC 2006 Pathphysiology of RANK ligand (RANKL) and osteoprotcgerin (OPG). Ann Endocrinol (Paris) 67:139-141.
39. Yamamoto Y, Udagawa N, Matsuura S, Nakamichi Y, Horiuchi H. Hosoya A, Nakamura M, Ozawa H, Takaoka K, Renninger JM, Noguchi T, Takahashi N 2006 Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-κB ligand. Endocrinology 147:3366-3374.
40. Dunford JE, Kavanagh KL, Rogers MJ, Opperman U, Ebetino FH, Russell RG 2007 Kinetic analysis of conformational changes ion farnesyl pyrophosphate synthase induced by nitrogen containing bisphosphonates. Bone 40:261M.
41. Papapoulos SE 2006 Bisphosphonate actions: Physical chemistry revisited. Bone 38:613-616.
42. Coxon FP, Thompson K, Roelofs AJ, Ebetini FH. Rogers MJ 2008 Visualizing mineral binding and uptake of bisphonates by osteoclasts and non-resorbing cells. Bone 42:848-860.
43. Roelofs AJ, Thompson K, Gordon S. Rogers MJ 2006 Molecular mechanisms of action of bisphosphonates: Current status. Clin Cancer Res 12:6222s- 6230s.
44. Dunford JE, Kwaasi AA, Rogers MJ, Bernett BL, Ebetino FH, Russell RG, Oppermann U. Kavanaah KL 2008 Structure-activity relationships among nitrogen containing bisphosphonates in clinical use and other analogues: Time-dependent inhibition of human farnesyl pyrophosphate synthase. J Med Chem 51:2187-2195.
45. Cremers SCLM, Pillai G, Papapoulos SE 2005 Pharmacokinetics/ pharmacodynamics of bisphosphonates. Clin Pharmacokinet 44:551-570.
46. Papapoulos SE, Cremers SC 2007 Prolonged bisphosphonate release after treatment in children. N Engl J Med 356:1075-1076.
47. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CYC 2005 Severly suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294-1301.
48. Liberman UA, Weiss SR. Broil J, Minne HW, Quan H, Bell NH. Rodriguez-Portales J, Downs RW Jr. Dequeker J, Favis M 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443.
49. Recker R. Lappe J, Davies KM, Heaney R 2004 Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res 19:1628-1633.
50. Cummings SR, Karpf DB, Harris F, Genant HK. Ensrud K, LaCroix AZ, Black DM 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289.
51. Kimmel DB, Recker RR, Gallagher JC, Vaswani AS, Aloia JF 1990 A comparison of iliac bone histomorphometric data in post- menopausal osteoporotic and normal subjects. Bone Miner 11:217-235.
52. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG 2008 Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22:346-350.
53. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF. Gilsanz V, Guise T, Koka S, McCauley LK, MeGowan J, Mckee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E 2007 Bisphosphonale-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone Mineral Research. J Bone Miner Res 22:1479- 1491.
54. Woo SB, Hellstein JW, Kalmar JR 2006 Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753-761.
55. Hoff AO, Toth BB, Altundag K, Johnson MM. Warneke CL, Hu M. Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN 2008 Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826-836.
56. Marx RE, Cillo JE, Ulloa JJ 2007 Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention and treatment. J Oral Maxillofac Surg 65:2397-2410.
57. Khosla S, Burr D, Cauley J. Dempster DW, Ebeling PR, Felsenberg D, Gagel RF. Gilsanz V, Guise T. Koka S. McCauley LK, MeGowan J, Mckee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH. Watts N. Woo SB, Shane E 2008 Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 66:1320-1321.
58. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S 2007 Estrogen prevents bone loss via estrogen receptor alpha and induction of fas ligand in osteoclasts. Cell 130:811-823.
59. Kousteni S, Bellido T, Plotkin Ll, O'Brien CA, Bodenner DL, Han L, Han K, DiGregoria GB. Katzenellenbogen JA. Katzenellenbogen BS, Roberson PK. Weinstein RS, Jilka RL, Manolagas SC 2001 Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: Dissociation from transcriptional activity. Cell 104:719-730.
60. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S 2000 Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106:1553-1560.
61. Charatcharoenwitthaya N, Khosla S, Atkinson EJ, McCready LK. Riggs BL 2007 Effect of blockade of TNF-a and interleukin-1 action on bone resorption in early postmenopausal women. J Bone Miner Res 22:724-729.
62. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL 2003 Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111:1221-1230.
63. Hall JM, McDonnell DP 2005 Coregulators in nuclear estrogen receptor action: From concept to therapeutic targeting. Mol Interv 5:343-357.
64. Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, Suda T, Matsuo K 2006 Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 4:111-121.
65. Lee SH, Rho J, Jeong D, Sul JY, Kim T, Kim N, Kang JS, Miyamoto T, Suda T, Lee SK, Pignolo RJ, Koczon-Jaremko B, Lorenzo J, Choi Y 2006 v-ATPase Vo subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med 12:1403-1408.
66. Yao Z. Li P, Zhang Q, Schwartz EM, Keng P, Arbini A, Boyce BF, Xing L 2006 Tunor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression. J Biol Chem 281:11846.
67. Zhang Q, Guo R, Lu Y, Zhao Q, Schwartz EM, Huang J, Chen D, Jin ZG, Boyce BF, Xing L 2008 VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism. J Biol Chem 283:13491-13499.
68. Young DW, Hassan MQ, Pratap J, Galindo M, Zaidi SK. Lee SH, Yang X, Xie R, Javed A. Underwood JM, Furcini Hi P, Imbalzano AN, Renman S, Nickerson JA, Montecino MA, Lian JB, Stein JL, Van Wijnen AJ, Stein GS 2007 Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2. Nature 445:442-446.
69. Hassan MQ, Tare R, Lee SH, Mandeville M, Weiner B, Montecino M, Van Wijnen AJ, Stein JL, Stein GS, Lian JB 2007 HOXA10 controls osteoblastogenesis by directly activating bone regulatory and phenotypic genes. Mol Cell Biol 27:3337-3352.
70. Lian JB. Stein GS, Javed A. Van Wijnen AJ, Stein JL, Montecino M, Hassan MQ, Gaur T. Lengner CJ, Young DW 2006 Networks and hubs for the transcriptional control of osteoblastogenesis. Rev Endocr Metab Disord 7:1-16.
71. Gaur T, Lengner CJ, Hovhannisyan H. Bhat RA, Bodine PV, Komm BS, Javed A, Van Wijnen AJ, Stein JL, Stein GS, Lian JB 2005 Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 280:33132-33140.
72. Baron R, Rawadi G 2007 Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148:2635-2643.
73. Balemans W, Van Hul W 2007 The genetics of low-density lipoprotein receptor-related protein 5 in bone: A story of extremes. Endocrinology 48:2622-2629.
74. Glass DA, Karsenty G 2007 In vivo analysis of Wnt signaling in bone. Endocrinology 148:2630-2634.
75. Canalis E, Giustina A, Bilezikian JP 2007 Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905-916.
76. Sawakami K, Robling AG, Ai M, Pitner ND, Liu D, Warden SJ, Li J, Maye P, Rowe DW, Duncan RL, Warman ML, Turner CH 2006 The WNT co-receptor LRP5 is essential for skeletal mechanotransduction, but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem 281:23698-23711.
77. Hens JR, Wilson KM, Dann P, Chen X, Horowitz MC. Wysolmerski JJ 2005 TOPGAL mice show that the canonical Wnt signaling pathway is active during bone development and growth and is activated by mechanical loading in vitro. J Bone Miner Res 20:1103-1113.
78. Robinson JA, Chatterjee-Kishore M. Yaworsky PJ, Cullen DM, Zhao W. Li C. Kharode Y, Sauter L, Babij P, Brown EL, Hill AA, Akhter MP, Johnson ML, Recker RR, Komm BS, Bex FJ 2006 WNT/beta-catenin signaling is a normal physiological response to mechanical loading in bone. J Biol Chem 281:31720-31728.
79. Balemans W, Van Hul W 2006 Human genetics of SOST. J Musculoskelet Neuronal Interact 6:355-356.
80. Ke HZ, Ominsky M. Li X, Simonet S, Lacey DL, Paszty C 2006 Bone anabolism achieved by reducing sclerostin bioavailability with an anti-sclerostin antibody. J Musculoskelet Neuronal Interact 6:359-360.
81. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Lantham JA 2003 Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22:6267-6276.
82. Loots GG, Kneissel M. Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM 2005 Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 15:928-935.
83. Keller H, Kneissel M 2005 SOST is a target gene for PTH in bone. Bone 37:148-158.
84. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL 2005 Chronic elevation of PTH in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577-4583.
85. O'Brien CA, Plotkin LI, Galli C, Goellner J, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T 2008 Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One 3:32942.
86. Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MJ, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido T, Harris SE, Turner CH 2008 Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 283:5866-5875.
87. Compston JE 2007 Skeletal actions of intermittent parathyroid hormone: Effects on bone remodelling and structure. Bone 40:1447-1452.
88. Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, Weinstein RS, O'Brien CA, Manolagas SC, Jilka RL 2003 Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 278:50259-50272.
89. Jilka RL 2007 Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40:1434-1446.
90. Mundy GR, Elefteriou F 2006 Boning up on ephrin signaling. Cell 126:441-443.
91. Mundy GR, Edwards JR 2007 The osteoclast-not always guilty. Cell Metab 6:157-159.
92. Dean T. Linglart A, Mahon MJ, Bastepe M, Jüppner H, Potts JT Jr, Gardella TJ 2006 Mechanisms of ligand binding to the parathyroid hormone (PTH)/PTH-related protein receptor: Selectivity of a modified PTH(1-15) radioligand for GalphaS-coupled receptor conformations. Mol Endo 20: 931-943.
93. Dean T, Villadarga JP, Potts JT Jr, Gardella TJ 2008 Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor. Mol Endocrinol 22:156-166.
94. Wüthrich RP, Martin D, Bilezikian JP 2008 The role of calcimimetics in the treatment of hyperparathyroidism. Eur J Clin Invest 37:915-922.
95. Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge R, Schwanauer LE, Olson KA, Klassen P, Bilezikian JP 2007 Cinacalcet HCI reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 92:3803-3808.
96. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback DM 2005 Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90:135-141.
97. Wilder L. Gamse R, Seuwen K, Buhl T, Berrli R, Breitenstein W, Graw S, Reynolds C, Bruin G, Belleli R, Klickstein L. John MR 2008 A novel calcium-sensing receptor antagonist leads to dose-dependent transient release of parathyroid hormone after oral administration to healthy volunteers. J Bone Miner Res 23:S49.
98. Fitzpatrick LA, Brennan E, Kumar S, Matheny C, Yi B. McLaughlin M, Phillips J, Skordos L, Ethgen D 2008 Rona- caleret, a novel calcium-sensing receptor antagonist, demonstrates potential as an oral bone-forming therapy in healthy postmenopausal women. J Bone Miner Res 23:S50.
99. Martin TJ, Sims NA 2005 Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11:76-81.
100. Karsdal M, Martin TJ, Bollerslev J, Christiansen C, Henriksen K 2007 Are non-resorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res 22:487-494.
101. Marzia M, Sims NA, Voit S, Migliaccio S, Taranta A, Bernadini S, Faraggiana T, Yoneda T, Mundy GR, Boyce BF, Baron R, Teti A 2000 Decreased c-src expression enhances osteoblastic differentiation and bone formation. J Cell Biol 151:311-320.
102. Schaller S, Henriksen K, Sorensen MG, Karsdal MA 2005 The role of chloride channels in osteoclasts: C1C-7 as a target for osteoporosis treatment. Drug News Perspect 18:489-495.
103. Allan EH, Hausler KD, Wei T, Gooi JH, Quinn JM, Crimeen-Irwin B, Pompolo S, Sims NA, Gillespie MT, Onyia JE, Martin TJ 2008 EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. J Bone Miner Res 23:1170-1181.
104. Ominsky M, Stouch B, Doellgast G, Gong J, Cao J, Gao Y, Tipton B, Haldankar R, Winters A, Chen Q, Graham K, Zhou L, Hale M, Henry A, Lightwood D, Moore A, Popplewell A, Robinson M, Vlasseros F, Jolette J, Smith SY, Kostenuik PJ, Simonet WS, Lacey DL. Paszty C 2006 Administration of sclerostin monoclonal antibodies to female cynomolgus monkeys results in increased bone formation, bone mineral density and bone strength. J Bone Miner Res 21:S1;S44.
105. Ominsky MS, Warmington KS. Asuncion FJ, Tan HL, Gri- santi MS, Geng Z, Stephens P, Henry A, Lawson A, Light- wood D, Perkins V, Kirby H, Moore A, Robinson M, Li X, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C 2006 Sclerostin monoclonal antibody treatment increases bone strength in aged osteopenic ovariectomized rats. J Bone Miner Res 21:S1;S44.
106. Bandyopadhyay A, Tsuji K, Cox K, Harfe BD, Rosen V, Tabin CJ 2006 Genetic analysis of the roles of BMP2, BMP4, and BMP7 in limb patterning and skeletogenesis. PLoS Genet 2:2116-2130.
107. Devlin RD, Du Z, Pereira RC, Kimble RB, Economides AN, Jorgetti V, Canalis E 2003 Skeletal overexpression of noggin results in osteopenia and reduced bone formation. Endocrinology 144:1972-1978.
108. Tsuji K, Bandyopadhyay A. Harfe BD, Cox K. Kakaar S, Gerstenfeld L, Einhorn T, Tabin CJ, Rosen V 2006 BMP2 activity, although dispensible for bone formation, is required for the initiation of fracture healing. Nat Genet 38:1424-1429.
109. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY. Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O. Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441.
110. Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB for the Treatment of Osteoporosis with PTH Study Group 2007 Effect of recombinant human parathyroid hormone (1-84) on vertebral fractures and bone mineral density in postmenopausal women with osteoporosis. Ann Intern Med 146:326-339.
111. Girotra M, Rubin MR, Bilezikian JP 2006 The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord 7:113-121.
112. Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R 2005 Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 11:566-575.
113. Ettinger B, San Martin JA, Crans G, Pavo I 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745-751.
114. Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP 2008 Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 93: 3785-3793.
115. Black DM, Greenspan SL, Ensrud KE, Palermo L, MeGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ; PaTH Study Investigators 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215.
116. Finkelstein JS. Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 25:1216-1226.
117. Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH 2005 Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: Results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 20:1905-1911.
118. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ 2005 One year of alendronate after one year of parathyroid hormone (1-84). N Engl J Med 353:555-565.